Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025British Journal of HaematologyOpen Access

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG‐MESRAT study

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMaximilian SchönungSRSilvia RathmannSRSenthilkumar Ramamoorthy

Discussion

Loading...

Member takes

Overview

Investigator-initiated trial reveals DNA methylation signatures predict azacitidine response in JMML patients, indicating monitoring potential.

Key Points

  • DNA methylation subgroup classification is linked to clinical response after azacitidine therapy in JMML patients.
  • Pharmacodynamic activity of azacitidine can be effectively monitored in peripheral blood and bone marrow.
  • Changes in variant allele frequencies did not correlate with therapeutic outcomes in the studied cohort.
  • The study highlights the potential for using DNA methylation patterns from blood samples as predictive biomarkers.

Cite This Study

Schönung et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d647923d3https://doi.org/10.1111/bjh.70046
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of chromatin accessibility associated with azacitidine response in higher-risk myelodysplastic neoplasms2025
  2. 2Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements2025
  3. 3Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML2025
  4. 4Azacitidine and decitabine show distinct response patterns in pediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukemia before HSCT: a systematic review and quantitative analysis2026
  5. 5MRD-guided azacitidine maintenance improves outcomes in molecularly persistent pediatric core-binding factor AML: A retrospective cohort study2025